🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 30/09/2015 | 102,08 | 105,84 | 101,58 | 104,14 | +4,32% | 4,17% | 2.864.000 |
| 29/09/2015 | 97,84 | 105,46 | 97,45 | 99,83 | +1,35% | 8,19% | 3.783.500 |
| 28/09/2015 | 103,72 | 104,50 | 97,79 | 98,50 | -4,63% | 6,47% | 3.948.400 |
| 25/09/2015 | 112,31 | 113,38 | 101,00 | 103,28 | -7,05% | 11,02% | 3.395.500 |
| 24/09/2015 | 110,30 | 112,94 | 109,02 | 111,11 | -0,67% | 3,55% | 2.671.700 |
| 23/09/2015 | 114,26 | 115,88 | 108,45 | 111,86 | -2,23% | 6,50% | 3.310.200 |
| 22/09/2015 | 116,42 | 116,99 | 110,41 | 114,41 | -3,20% | 5,65% | 4.493.700 |
| 21/09/2015 | 124,87 | 126,78 | 117,58 | 118,19 | -4,81% | 7,37% | 2.583.100 |
| 18/09/2015 | 132,26 | 132,26 | 123,98 | 124,16 | -8,16% | 6,26% | 4.404.900 |
| 17/09/2015 | 134,03 | 136,62 | 133,11 | 135,19 | +1,14% | 2,62% | 1.175.900 |
| 16/09/2015 | 135,99 | 136,97 | 131,42 | 133,66 | -1,32% | 4,08% | 1.186.500 |
| 15/09/2015 | 135,59 | 136,49 | 133,40 | 135,45 | +0,44% | 2,28% | 1.115.900 |
| 14/09/2015 | 136,31 | 136,67 | 132,71 | 134,85 | +0,59% | 2,91% | 1.390.200 |
| 11/09/2015 | 131,00 | 134,13 | 130,10 | 134,06 | +1,56% | 3,08% | 1.056.200 |
| 10/09/2015 | 129,21 | 133,71 | 129,21 | 132,00 | +1,58% | 3,48% | 981.700 |
| 09/09/2015 | 134,49 | 134,61 | 129,31 | 129,95 | -2,37% | 3,94% | 1.104.600 |
| 08/09/2015 | 129,93 | 133,49 | 127,97 | 133,11 | +4,82% | 4,25% | 1.346.900 |
| 04/09/2015 | 124,30 | 128,04 | 123,81 | 126,99 | +0,36% | 3,40% | 1.240.700 |
| 03/09/2015 | 130,13 | 130,76 | 126,15 | 126,53 | -1,91% | 3,54% | 1.010.200 |
| 02/09/2015 | 125,56 | 129,10 | 124,00 | 129,00 | +4,00% | 4,06% | 1.486.900 |
| 01/09/2015 | 124,07 | 127,42 | 123,00 | 124,04 | -2,73% | 3,56% | 1.998.500 |
| 31/08/2015 | 132,71 | 134,24 | 127,41 | 127,52 | -4,87% | 5,15% | 1.711.100 |
| 28/08/2015 | 132,39 | 134,53 | 131,03 | 134,05 | +0,22% | 2,64% | 1.240.200 |
| 27/08/2015 | 131,49 | 133,99 | 129,85 | 133,75 | +2,80% | 3,15% | 2.017.500 |
| 26/08/2015 | 124,60 | 130,29 | 121,81 | 130,11 | +7,38% | 6,81% | 2.515.900 |
| 25/08/2015 | 126,71 | 126,84 | 120,89 | 121,17 | +1,59% | 4,70% | 2.644.400 |
| 24/08/2015 | 117,54 | 128,15 | 112,89 | 119,27 | -4,94% | 12,98% | 3.315.800 |
| 21/08/2015 | 131,33 | 133,43 | 125,36 | 125,47 | -5,60% | 6,14% | 2.505.000 |
| 20/08/2015 | 138,69 | 140,66 | 132,63 | 132,91 | -6,06% | 5,79% | 1.861.700 |
| 19/08/2015 | 140,45 | 142,49 | 137,85 | 141,48 | +1,23% | 3,30% | 1.339.000 |